Treatment modalities in comparison: When do clinical differences emerge?

Nephrology Dialysis Transplantation

Volumn 15, Issue SUPPL. 1, 2000, Pages 29-35

  Locatelli, Francesco ^a   Manzoni, C ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; BICARBONATE; DIALYSIS FLUID;

ANEMIA; BIOCOMPATIBILITY; CONFERENCE PAPER; DIALYSIS; DIALYSIS MEMBRANE; FOLLOW UP; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INFECTION COMPLICATION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; NUTRITION; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL TIME; UREMIA;

EID: 0033995632     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.ndt.a027960     Document Type: Conference Paper

References (40)

1. 2-microglobulin amyloidosis in haemodialysis: a prospective post-mortem study. Kidney Int 1997; 51: 1928-1932
2. Hakim RM. Clinical implications of haemodialysis membrane biocompatibility. (Perspectives in Clinical Nephrology.) Kidney Int 1993; 44: 484-494
3. Cheung AK, Leypoldt JK. The haemodialysis membranes: a historical perspective, current state and future prospect. Semin Nephrol 1997; 17: 196-213
4. Jacobs C. Membrane biocompatibility in the treatment of acute renal failure: what is the evidence in 1996? Nephrol Dial Transplant 1997; 12: 38-42
5. Wheeler DC. Cardiovascular disease in patients with chronic renal failure. Lancet 1996; 348: 1673-1674
6. Chanard J, Brunois IP, Melin JP, Lavaud S, Toupance O. Long-term results of dialysis therapy with a highly permeable membrane. Artif Organs 1982; 6: 261-266
7. Skroeder NR, Jacobson SH, Lins LE, Kjellstrand CM. Biocompatibility of dialysis membranes is of no importance for objective or subjective symptoms during or after haemodialysis. Trans Am Soc Artif Intern Organs 1990; 36: 637-639
8. Bergamo Collaborative Dialysis Group. Acute intradialytic wellbeing: results of a clinical trial comparing polysulfone with Cuprophan. Kidney Int 1991; 40: 714-719
9. Collins DM, Lambert MB, Tannenbaum JS, Oliverio M, Schwab SJ. Tolerance of haemodialysis: a randomised, prospective trial of high-flux versus conventional high-efficiency haemodialysis. J Am Soc Nephrol 1993; 4: 148-153
10. Locatelli F, Mastrangelo F, Redaelli B, Ronco C, Marcelli D, La Greca G, Orlandini G and the Italian Cooperative Dialysis Study Group. Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. Kidney Int 1996; 50: 1293-1302
11. Altieri P, Sorba GB, Bolasco PG, Bostrom M. Asproni E, Ferrara R, Bolasco F, Casu D, Cossu M, Cabiddu GF, Ganadu G, Pinna M, La Rocca M, Cadinu F, Serra G, Passaghe M, Sardininan Collaborative Study Group of On-Line Hemofiltration, Italy. On-line predilution hemofiltration versus ultrapure high-flux hemodialysis: a multicenter prospective study in 23 patients. Blood Purif 1997; 15: 169-181
12. McKane WS, Tattersall JE, Farrington K. Preservation of residual renal function in high flux haemodialysis. Nephrol Dial Transplant 1994; 9: 1686 (Abstract)
13. Caramelo C, Alcazar R, Gallar P, Teruel JL, Velo M, Ortega O, Galera A, Da Silva M. Choice of dialysis membrane does not influence the outcome of residual renal function in haemodialysis patients. Nephrol Dial Transplant 1994; 9: 675-677
14. 2-microglobulin levels in chronic haemodialysis patients. J Am Soc Nephrol 1996; 7: 472-478
15. Schiffl H, Hartmann J, Lang S. Biocompatible membranes slow the decline of residual renal function in patients undergoing regular haemodialysis. Nephrology 1997; 3 (Suppl. 1): 415 (Abstract)
16. McCarthy JT, Jenson BM, Squillace DP, Williams AW. Improved preservation of residual renal function in chronic haemodialysis patients using polysulfone dialyzers. Am J Kidney Dis 1997; 29: 576-583
17. Gutierrez A, Bergstrom J, Alvestrand A. Protein catabolism in sham haemodialysis: the effect of different membranes. Clin Nephrol 1992; 38: 20-29
18. Lim VS, Bier DM, Flanigam M, Symreng T. The effect of haemodialysis on protein metabolism. J Am Soc Nephrol 1990; 1: 366
19. Lindsay RM, Spanner E, Heidenheim AP, Burton H, Lindsay S. Lefebvre JMJ. A multicentre study of short hour dialysis using AN69 - preliminary results. ASAIO Trans 1991; 37: 465-467
20. Parker TF, Wingard RL, Husni L, Ikizler TA, Parker RA, Hakim RM. Effect of the membrane biocompatibility on nutritional parameters in chronic haemodialysis patients. Kidney Int 1996; 49: 551-556
21. Vanholder R, Ringoir S, Dhondt A, Hakim RM. Phagocytosis in uremic and haemodialysis patients: a prospective and cross-sectional study. Kidney Int 1991; 39: 320-327
22. Bloembergen WE, Stannard DC, Port FK, Wolfe RA, Pugh JA, Jones CA, Greer JW, Golper TA, Held PJ. Relationship of dose of haemodialysis and cause-specific mortality. Kidney Int 1996; 50: 557-565
23. Kobayashi H, Ono T, Yamamoto N, Fukuda T, Yamada S. Kai C, Kataoka H, Kobayashi T, Sonoda T. Removal of high molecular weight substances with large pore size membrane (BK-F). Kidney Dial 1993; 34 (Suppl.): 154-157
24. Ifudu O, Feldman J, Friedman EA. The intensity of haemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med 1996; 334: 420-425
25. 2-microglobulin deposition in bone in chronic renal failure. Kidney Int 1991; 39: 990-995
26. 2-microglobulin: a new form of amyloid protein associated with chronic haemodialysis. Kidney Int 1986; 30: 358-390
27. Van Ypersele de Strihou C, Jadoul M, Malghem J, Maldague B, Jamart J and the Working Party on Dialysis Amyloidosis. Effect of dialysis membrane and patient's age on signs of dialysis related amyloidosis. Kidney Int 1991; 39: 1012-1019
28. Bonomini V, Coli L, Feliciangeli G, Nanni Costa A, Scolari MP. Long-term comparative evaluation of synthetic and cellulosic membranes in dialysis. Int J Artif Organs 1994; 17: 392-398
29. Kuchle C, Fricke H, Held E, Schiffl H. High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis. Am J Nephrol 1996; 16: 484-488
30. 2-microglobulin and dialysis-associated amyloidosis. Nephrology 1997; 3 (Suppl. 1): 404 (Abstract)
31. Charra B, Calemard E, Uzan M, Terrat JC, Vanel T, Laurent G. Carpal tunnel syndrome, shoulder pain and amyloid deposits in long-term haemodialysis patients. Proc EDTA-ERA 1984; 21: 291-295
32. Locatelli F, Marcelli D, Conte F, Limido A, Malberti F, Spotti D. Morbidity and mortality in ESRD patients on convective or on diffusive extracorporeal treatment. Nephrol Dial Transplant 1997; 12: A174 (Abstract)
33. Churchill DN, Wayne Taylor D, Tomlinson CW. Beecroft ML, Gorman J, Stanton E. Effect of high-flux haemodialysis on cardiac structure and function among patients with end-stage renal failure. Nephron 1993; 65: 573-577
34. Hornberger JC, Chernew M, Petersen J, Garber AM. A multivariate analysis of mortality and hospital admissions with high flux dialysis. J Am Soc Nephrol 1992; 3: 1227-1237
35. Woods HF. Evidence for a biocompatibility-independent effect of high-flux dialysis on improved patient survival. Nephrology 1997; 3 (Suppl. 1): 415 (Abstract)
36. Hakim RM, Held PJ, Stannard DC, Wolfe RA, Port FK, Daugirdas JT, Agodoa L. Effect of the dialysis membrane on mortality of chronic haemodialysis patients. Kidney Int 1996; 50: 566-570
37. Locatelli F. Influence of membranes on morbidity. Nephrol Dial Transplant 1996; 11 (Suppl. 2): 116-120
38. Eknoyan G, Levey AS, Beck GJ, Agodoa LY, Daugirdas JT, Kusek JW, Levin NW, Schulman G. The Haemodialysis (HEMO) study: rationale for selection of interventions. Semin Dial 1996; 9: 24-33
39. HEMO Study Group (prepared by Eknoyan G, Beck GJ, Kusek JW, Levin NW). Progress of the Haemodialysis (HEMO) study. Nephrology 1997; 3 (Suppl. 1): S419 (Abstract)
40. Locatelli F, Marcelli D, Conte F, Limido A, Malberti F, Spotti D. Morbidity and mortality in ESRD patients on convective or on diffusive extracorporeal treatment. Kidney Int 1999; 55: 286-293